ライフサイエンスコーパス: clodronate

1 non-U.S.-approved formulations (neridronate, clodronate).

2 ) group 5 = diabetes + periodontitis + LDD + clodronate.

3 tive intratracheal instillation of liposomal clodronate.

4 y subconjunctival (SC) delivery of liposomal clodronate.

5 gues and the antimacrophage agent, liposomal clodronate.

6 etion of alveolar macrophages with liposomal clodronate.

7 y treating B6 mice with liposomes containing clodronate.

8 n after macrophage depletion using liposomal clodronate.

9 hibited by the antiosteolytic bisphosphonate clodronate.

10 travenous injection of liposome-encapsulated clodronate.

11 effects were indistinguishable from those of clodronate.

12 antiresorptive and antimacrophage effects of clodronate.

13 ker); and intravenous injection of liposomal clodronate.

14 IL17RA(-/-) mice using liposomes loaded with clodronate.

15 is-free interval was slightly increased with clodronate (0.74, 0.55-1.00; p=0.047).

16 Patients were randomized to receive oral clodronate 1,600 mg/d or a placebo for 2 years starting

17 acid (4 mg intravenously every 6 months) or clodronate (1,600 mg/d orally) be considered as adjuvant

18 domly assigned in a 1:1 ratio to either oral clodronate 1600 mg daily for 3 years (n=1662) or placebo

19 igned to take four tablets per day of sodium clodronate (2080 mg) or matching placebo for up to 3 yea

20 ld C57BL/10J mice with liposome-encapsulated clodronate 48 h before 35 min of hepatic ischemia with b

21 ither phosphate-buffered saline (control) or clodronate (a macrophage depleting drug) at 15 weeks pos

22 crophage depletion via liposomal delivery of clodronate, a first-generation bisphosphonate, mitigates

23 re-treatment of the recipient with liposomal clodronate, a macrophage depleting agent, with the goal

24 Conversely, in mice with clodronate-ablated macrophages, neutrophils extravasate,

25 Systemic depletion of macrophages with clodronate abolished CDC-mediated cardioprotection.

26 c cells by injection of liposomes containing clodronate abolished diabetes, although inflammation rem

27 General macrophage depletion by clodronate abolished this iNKT activation.

28 M using intracerebroventricular injection of clodronate abrogates the reactive oxygen species product

29 cant benefits for zoledronic acid (ZOL) over clodronate acid (CLO) were seen in the Medical Research

30 Both EGTA and clodronate also prevented the bisphosphonate-induced inh

31 owever, treatment with liposome-encapsulated clodronate, an agent that depletes macrophages in vivo,

32 controlled trials assessed the use of sodium clodronate, an oral, first-generation bisphosphonate.

33 To compare the mechanism of action of clodronate and alendronate, effects on protein prenylati

34 The effects of clodronate and AppCCl2p on bone resorption, osteoclast n

35 Clodronate and DTR inhibited macrophage infiltration and

36 Two potent inhibitors, clodronate and etidronate, are already clinically approv

37 Unlike alendronate, clodronate and its metabolite did not affect prenylation

38 The use of mono and combined clodronate and LDD administrations may significantly red

39 evaluate the effect of mono and combined BP clodronate and LDD therapies in reducing gingival levels

40 aims of this study were to determine whether clodronate and liposome-encapsulated clodronate are meta

41 ause there are no direct comparisons between clodronate and pamidronate or zoledronic acid, the super

42 Most studies evaluated zoledronic acid or clodronate, and data are extremely limited for other bis

43 were depleted from mice by administration of clodronate, and their location and phenotype were examin

44 y the positive result of one trial of sodium clodronate, and we found no evidence of a benefit from t

45 x vivo with immunomagnetic beads) metabolize clodronate, and whether rat peritoneal macrophages metab

46 LDD; 4) group 4 = diabetes + periodontitis + clodronate; and 5) group 5 = diabetes + periodontitis +

47 whether clodronate and liposome-encapsulated clodronate are metabolized to adenosine 5'-(beta,gamma-d

48 ronate, risedronate, and lovastatin, but not clodronate, are blocked by geranylgeraniol, a precursor

49 acerebral injection of liposome-encapsulated clodronate at P5 significantly reduced vessel coverage a

50 he intratracheal administration of liposomal clodronate attenuated particulate matter-induced IL-6 pr

51 B6) mice by i.v. administration of liposomal clodronate before allogeneic bone marrow transplantation

52 in the airways were depleted using liposomal clodronate before infection, this resulted in a signific

53 ection of the macrophage-depleting liposomal clodronate before radiotherapy can increase the antitumo

54 acerebral injection of liposome-encapsulated clodronate before transient middle cerebral artery occlu

55 nd could be inhibited by addition of EGTA or clodronate, both of which chelate calcium ions.

56 Pretreatment of NTN mice with clodronate but not control liposomes completely prevente

57 protocol B-34 aims to ascertain whether oral clodronate can improve outcomes in women with primary br

58 Liposome-encapsulated clodronate caused an increase in peritoneal macrophage a

59 mokine receptor type 2 (CCR2) antagonist and clodronate (CLD) were respectively administered to N12W

60 gimens and IV zoledronic acid (ZOL) and oral clodronate (CLO) in 1960 patients with newly diagnosed m

61 ence of improvement in overall survival with clodronate compared with placebo (HR 1.12, 0.89-1.42; p=

62 e with metastatic disease from use of sodium clodronate compared with placebo was seen in overall sur

63 Depletion of monocytic phagocytes with clodronate completely prevented MCMV from delaying tumor

64 ippostrongylus brasiliensis and treated with clodronate-containing liposome to deplete macrophages or

65 capsular sinus CD169-positive macrophages by clodronate-containing liposome was associated with a lac

66 Thus, we predicted that injection of clodronate-containing liposomes (CLs), which selectively

67 rophages using subconjunctival injections of clodronate-containing liposomes before corneal infection

68 Depletion of macrophages by clodronate-containing liposomes blocked the tumor-promot

69 normally developed spleens by treatment with clodronate-containing liposomes demonstrated that these

70 Clodronate-containing liposomes deplete mice of splenic

71 macrophages by intranasal administration of clodronate-containing liposomes in caspase-9 inhibitor-t

72 In vitro, clodronate-containing liposomes killed activated murine

73 Mice treated with clodronate-containing liposomes show markedly less tumor

74 ed mice and compared tumor development using clodronate-containing liposomes to deplete macrophages i

75 Depletion of macrophages with clodronate-containing liposomes was also associated with

76 Treatment of PVC-211 MuLV-infected rats with clodronate-containing liposomes, which specifically kill

77 phages were depleted from ilea of mice using clodronate-containing liposomes.

78 Our data also show that clodronate depletion of AMs leads to replenishment, but

79 Clodronate depletion of circulating monocytes, by contra

80 Liposomally encapsulated clodronate (dichloromethylene diphosphonate) has previou

81 splenic phagocytic APCs by i.v. injection of clodronate- (dichloromethylene diphosphonate) containing

82 ages by intranasal instillation of liposomal clodronate diminished pneumococcal clearance.

83 which is based on intracerebral injection of clodronate disodium salt (CDS) into the PFC of adolescen

84 The i.v. administration of clodronate effectively reduced total BALF cell numbers,

85 ival administration of liposome-encapsulated clodronate efficiently diminished resident ocular surfac

86 eolar macrophages were depleted with inhaled clodronate, ELD607 was no longer able to resolve inflamm

87 al macrophages with the macrophagicidal drug clodronate eliminated the latex beads' protective effect

88 peritoneal macrophages after depletion with clodronate encapsulated liposomes.

89 Macrophage ablation by injection of clodronate-encapsulated liposomes increases blood platel

90 hamsters were treated, intratracheally, with clodronate-encapsulated liposomes or control liposomes a

91 Treatment with clodronate-encapsulated liposomes resulted in significan

92 Some mice were also given clodronate-encapsulated liposomes to deplete macrophages

93 nstitution of apoptosis with BH3 mimetics or clodronate-encapsulated liposomes.

94 macrophages metabolize liposome-encapsulated clodronate, following in vivo administration.

95 s or older on study entry showed benefits of clodronate for recurrence-free interval (0.75, 0.57-0.99

96 l);Pkhd1-Cre mice by treating with liposomal clodronate from postnatal day 10 until day 24.

97 Intravenous clodronate given after pain was established had the oppo

98 Clodronate, given to patients with primary operable brea

99 tion was noted in 23 of 1612 patients in the clodronate group and 12 of 1623 patients in the placebo

100 ence to treatment at 3 years was 56% for the clodronate group and 60% for the placebo group.

101 -4 diarrhoea was noted in 28 patients in the clodronate group and in ten in the placebo group.

102 not differ between groups (286 events in the clodronate group vs 312 in the placebo group; hazard rat

103 ible case of osteonecrosis of the jaw in the clodronate group.

104 intracebroventricular injection of liposomal clodronate, had little or no effect on the response of l

105 at a first-generation bisphosphonate, sodium clodronate, improves overall survival in men with metast

106 ZOL is preferred over oral clodronate in newly diagnosed patients with MM because o

107 e infiltration by systemic administration of clodronate-incorporated liposomes fails to suppress LSI-

108 Clodronate-induced depletion of the alveolar macrophage

109 Consistent with these findings, clodronate-induced macrophage depletion results in a sig

110 Importantly, clodronate-induced macrophage depletion significantly at

111 (CB(1)R) inverse agonist (SR141716), and by clodronate-induced myeloid-cell depletion, but not by ge

112 Interestingly, macrophage depletion with clodronate inhibited the development of colitis, while t

113 lvaria also is blocked by mevalonate whereas clodronate inhibition is not.

114 re generated by the combination of liposomal clodronate injection, irradiation, and BM transplantatio

115 lled trials is modest but supports that oral clodronate, intravenous pamidronate, and intravenous zol

116 ted CCR2 chimeric mice by the combination of clodronate, irradiation, and bone marrow (BM) transplant

117 Clodronate is an alternative bisphosphonate approved wor

118 hese results provide proof-of-principle that clodronate is effective at sparing the number of donor B

119 Additionally, clodronate is not available in the United States.

120 somiasis with macrophage-depleting liposomal clodronate (LC) to define how macrophages mediate bladde

121 n the bladder by administration of liposomal clodronate led to higher UPEC burdens.

122 owed that delaying macrophage recruitment by clodronate liposome (-1d_CL, macrophage-delayed model) i

123 in the induction of LPC proliferation using clodronate liposome deletion of Kupffer cells and adopti

124 en identifies resistance factors that impair clodronate liposome function.

125 Interestingly, using a clodronate liposome model with targeted depletion of mat

126 nistic detail of phagolysosome formation and clodronate liposome processing.

127 Finally, clodronate liposome treatment in mice prevented PH in N(

128 Lastly, clodronate liposome treatment of TCR transgenic mice dep

129 Clodronate liposome treatment reduced initial liver mono

130 Clodronate liposome treatment significantly reduced the

131 g on day 1, which was virtually abolished by clodronate liposome treatment.

132 atment or peripheral macrophage depletion by clodronate liposome treatment.

133 Depleting macrophages (with clodronate liposome) and neutrophils (with anti-Ly6G/1A8

134 By day 14 after clodronate liposome, although both dural macrophages and

135 phages, through subconjunctival injection of clodronate liposome, attenuated lissamine green staining

136 Clodronate liposome-mediated depletion of infiltrating m

137 Clodronate liposome-mediated depletion of islet macropha

138 ost-AAI rAMs was studied in vivo by means of clodronate liposome-mediated depletion, adoptive transfe

139 ndent of lymphoid tissues but dependent on a clodronate liposome-sensitive population of liver-reside

140 AFIA mice had reduced CD68(+) cells, whereas clodronate liposome-treated mice had increased CD68(+) a

141 tion of these infiltrating macrophages using clodronate-liposome administration shows a significant r

142 on viral RNA abundance in the liver, whereas clodronate-liposome depletion of macrophages between day

143 Clodronate-liposome treatment depletes circulating monoc

144 The enhancing effect of clodronate-liposome treatment on infection (i) was shown

145 In clodronate-liposome-treated group, allograft hearts exhi

146 rophage depletion was achieved by daily i.v. clodronate liposomes (-1 day to +3 days) during AngII in

147 Antecedent Kupffer cell depletion with clodronate liposomes (0.5 mg/kg).

148 onducted to determine whether treatment with clodronate liposomes (CL(2)MDP-lip), which cause depleti

149 nvestigate this, we depleted phagocytes with clodronate liposomes (CL) in vivo through systemic deliv

150 Clodronate liposomes (Clo-Lip) have been widely used to

151 Moreover, depletion of SCS macrophages using clodronate liposomes abolished NK cell accumulation and

152 Clodronate liposomes and an anti-IL-1beta antibody were

153 ge activation by depleting these cells using clodronate liposomes and inhibiting the inflammasome wit

154 r competence and demonstrates the utility of clodronate liposomes as an important tool in the study o

155 , depletion of salivary gland macrophages by clodronate liposomes compromised the restoration of irra

156 In addition, the treatment of rats with clodronate liposomes depleted KCs and led to increased s

157 Depletion of monocytes with clodronate liposomes during CSD recovery prevented fibri

158 Importantly, the application of clodronate liposomes effectively depleted splenic and CN

159 depletion from the intratracheal delivery of clodronate liposomes enhanced Sftpc(I73T) -induced morta

160 ction, we depleted them by the inhalation of clodronate liposomes in an established mouse model of re

161 Depletion of phagocytic cells by clodronate liposomes in wild-type mice resulted in a red

162 Clodronate liposomes increased efferocytosis (clearance

163 th saline/WT, which was virtually ablated by clodronate liposomes independent of hypertension.

164 Intracisterna magna injection of clodronate liposomes indicated a comprehensive depletion

165 Postnatal injections of clodronate liposomes into female RUPP and sham offspring

166 ablating liver macrophages by treatment with clodronate liposomes largely abolished the beneficial me

167 was assessed by eliminating these cells with clodronate liposomes or silica.

168 n of CD206(+) macrophages using mannosylated clodronate liposomes promoted sustained pain in Pi16(-/-

169 pletion of alveolar macrophages with inhaled clodronate liposomes reduced both NK and T cell numbers

170 Depletion of peritoneal macrophages by clodronate liposomes reduced capsular fibrosis.

171 The depletion of blood monocytes with clodronate liposomes reduced neutrophil clustering in th

172 y intrathecal administration of mannosylated clodronate liposomes reduced the capacity of an HDAC6 in

173 However, Kupffer cell depletion with clodronate liposomes resulted in greater apoptosis and F

174 phage depletion in wild-type (WT) mice using clodronate liposomes resulted in impaired muscle regener

175 using splenectomized mice or treatment with clodronate liposomes suggested that macrophages in the s

176 After tumors were established, we used clodronate liposomes to ablate macrophages.

177 apoE-/- mice before and after treatment with clodronate liposomes to deplete tissue macrophages, comp

178 effects were mitigated in mice treated with clodronate liposomes to reduce circulating monocytes and

179 monstrated by depleting the macrophages with clodronate liposomes which effectively reduced inflammat

180 peritoneal macrophages were depleted (using clodronate liposomes) from PD-1(-/-) mice, the animals'

181 epletion of macrophages in the cornea (using clodronate liposomes) prior to injury significantly inhi

182 rone mice SNF(1) mice that were treated with clodronate liposomes, but not mice treated with vehicle,

183 is in vivo, induced by the administration of clodronate liposomes, can exacerbate the autoimmune phen

184 By selective depletion studies using clodronate liposomes, depleting monoclonal antibodies sp

185 s were not affected following treatment with clodronate liposomes, immunization of CCR2(-/-) mice, or

186 confirmed by depleting LPM with intrapleural clodronate liposomes, which abrogated the antitumoral me

187 ed for fitness and that confer resistance to clodronate liposomes, which are used to ablate immune ce

188 ated by alveolar macrophage depletion, using clodronate liposomes.

189 . bilis-infected Rag2(-/-) mice treated with clodronate liposomes.

190 mice that had been macrophage depleted using clodronate liposomes.

191 mice depleted of alveolar macrophages using clodronate liposomes.

192 animals after depletion of macrophages with clodronate liposomes.

193 Depletion of macrophages by clodronate-liposomes abrogates liver EphB2 messenger RNA

194 significantly elevated in mice treated with clodronate-liposomes at 3 and 5 days p.i., while IL-10 l

195 elevated in the cornea of mice treated with clodronate-liposomes at both 3 and 5 days p.i.

196 The elimination of macrophages by clodronate-liposomes attenuated NF-kappaB-induced liver

197 Both groups of inbred mice treated with clodronate-liposomes compared with PBS-liposomes (contro

198 Treatment with clodronate-liposomes did not affect the antigen-presenti

199 inactivation of monocyte lineage cells with clodronate-liposomes led to the suppression of pathologi

200 this monocytic cell population, using either clodronate-liposomes or gadolinium chloride, prevented p

201 and selective depletion of macrophages with clodronate-liposomes protects hearts against allograft r

202 Macrophage depletion using clodronate-liposomes resulted in a significant reduction

203 were determined in BALB/c mice treated with clodronate-liposomes vs control-treated mice.

204 e cornea of both groups of mice treated with clodronate-liposomes vs PBS-liposomes.

205 cterial plate counts in B6 mice treated with clodronate-liposomes were unchanged at 3 days and were h

206 methylene diphosphonate (Cl2MDP-liposomes or clodronate-liposomes) before priming mice with vesicular

207 elevated in both groups of mice treated with clodronate-liposomes.

208 depleted by treating recipient animals with clodronate-liposomes.

209 Herein, we used clodronate-loaded liposomes (CL) to locally deplete macr

210 Clodronate-loaded liposomes were used as a tool to deple

211 xpansion was abrogated by prior injection of clodronate-loaded liposomes, indicating a role for subca

212 l amygdala mannosylated liposomes containing clodronate (m-CLD; 0 or 25 mug/side, n = 13-14/group), a

213 le of macrophages or their susceptibility to clodronate may change with time.

214 y of utilizing liposomal delivery means that clodronate may not be an ideal means of preventing graft

215 Moreover, clodronate-mediated cell-depletion implicated Tim4(+) re

216 phoma depletion by CD20 mAb in vivo, whereas clodronate-mediated depletion of macrophages eliminated

217 Clodronate-mediated depletion of phagocytic cells marked

218 modulation of the myeloid population through clodronate-mediated depletion showed a partial abrogatio

219 At day 30, liposomal clodronate-mediated macrophage depletion reduced fibrosi

220 Liposomal clodronate-mediated macrophage depletion significantly r

221 iven to patients with primary breast cancer, clodronate might reduce the subsequent incidence of bone

222 In vivo, MPhi depletion (clodronate, MPhi Fas-induced apoptosis mice) and genetic

223 ype I, 97%), evaluating alendronate (n = 2), clodronate (n = 1), neridronate (n = 5), pamidronate (n

224 rrence of nonosseous metastases was similar (clodronate, n = 112; placebo, n = 128; P =.257), but the

225 uction in the occurrence of bone metastases (clodronate, n = 12; placebo, n = 28; HR, 0.44; 95% CI, 0

226 reduction in occurrence of bone metastases (clodronate, n = 63; placebo, n = 80; hazards ratio [HR],

227 re was a significant reduction in mortality (clodronate, n = 98; placebo, n = 129; P =.047) during th

228 e, risedronate, pamidronate, etidronate, and clodronate on apoptosis and signaling kinases.

229 tiinflammatory and antiresorptive effects of clodronate on macrophages and osteoclasts in vivo occur

230 Depleting macrophages using clodronate or conditionally deleting Glul from macrophag

231 ravenously with either liposome-encapsulated clodronate or empty liposomes prior to and after OBX or

232 phage depletion agent (liposome-encapsulated clodronate) or with a neutrophil depletion agent (cyclop

233 ptions recommended by the Panel include oral clodronate, oral ibandronate, and intravenous zoledronic

234 Moreover, clodronate pre-treatment increased durable donor-specifi

235 We found that liposomal clodronate pretreatment of C57BL/6 mice permitted establ

236 asal administration of liposome-encapsulated clodronate prior to bacterial inoculation.

237 epletion of splenic macrophages by liposomal clodronate protects against PIFA-induced chemoresistance

238 Notably, the liposome-encapsulated clodronate reduced the severity of LPS-induced neurodege

239 Macrophage depletion with clodronate reduced the tumor-infiltrating effector CD4 a

240 se changes, whereas depleting monocytes with clodronate resulted in a modest partial inhibition.

241 Macrophage depletion by liposomal clodronate resulted in a reversal of the beneficial effe

242 The clodronate screen identifies resistance factors that imp

243 r bisphosphonates, including pamidronate and clodronate, seem to be ineffective in this setting.

244 was associated with an increase in levels of clodronate-sensitive, phagocytic SiglecF(low) alveolar m

245 rom the fetal cerebral cortex with liposomal clodronate significantly increased the number of neural

246 Clodronate significantly reduced TAMs and splenic macrop

247 reating mice with i.v. liposome-encapsulated clodronate, significantly attenuated perfusate cytokine

248 ocyte ablation were used: systemic liposomal clodronate (sLC), inducible depletion using CD11b diphth

249 In either case, liposomal clodronate substantially decreased RBC destruction.

250 on injury in mice pre-treated with liposomal clodronate, suggesting the process was regulated by live

251 Thus, in AIHA, liposomal clodronate therapy may act like a temporary, medicinal s

252 utrophil depleting antibody (1A8), liposomal clodronate to deplete monocytes/macrophages, or PD032590

253 Use of liposomal clodronate to deplete resident AMs (rAMs) resulted in in

254 Mice were treated with liposomal clodronate to investigate the effect of macrophage deple

255 first time the use of liposome-encapsulated clodronate to selectively deplete macrophages during the

256 resulting in improved survival of liposomal clodronate-treated B6 recipients.

257 fa, Il-1beta, Il-10, Cxcl1, and iNos, in the clodronate-treated H. bilis-infected Rag2(-/-) mice comp

258 Injected eyes of IFN-gamma knockout or clodronate-treated macrophage-depleted mice were examine

259 These clodronate-treated mice also had increased expression of

260 tic cells were more numerous in MAFIA versus clodronate-treated mice and flow cytometric analyses of

261 f macrophages in the OE of both sham and OBX clodronate-treated mice were significantly reduced compa

262 eta1 serum levels and pSmad3 were reduced in clodronate-treated mice, but their reductions were insuf

263 ells and TAMs, was reduced in tumor cells of clodronate-treated mice.

264 When compared with vehicle-treated controls, clodronate-treated non-lupus-prone DBF(1) mice developed

265 caspase-3 in the OE and olfactory nerves of clodronate-treated OBX mice compared to liposome-treated

266 d in extracts from osteoclasts purified from clodronate-treated rabbits.

267 t reduction in bacterial colonization in the clodronate-treated Rag2(-/-) mice.

268 et, vascular endothelial growth factor A, in clodronate-treated tumor cells, which correlated with re

269 correlated with reduced vascular density in clodronate-treated tumors.

270 , 1.32+/-0.41 mm(3) in liposome-encapsulated clodronate-treated versus 3.04+/-0.72 mm(3) in saline-tr

271 Clodronate treatment affected the number of alternativel

272 Although clodronate treatment alone produced a peak level of bloo

273 Clodronate treatment also delayed the resolution of tiss

274 Tumors with clodronate treatment did not show decreased proliferatio

275 depletion of macrophages and osteoclasts via clodronate treatment had differential effects based on s

276 Furthermore, clodronate treatment hastened the onset of proteinuria a

277 In healing extraction sockets, clodronate treatment increased extraction socket trabecu

278 ion of monocytes or macrophages by liposomal clodronate treatment or genetic deficiency of macrophage

279 r, depletion of monocytes and macrophages by clodronate treatment or inhibition of gastric monocyte i

280 Similarly, depletion of macrophages by clodronate treatment prevented HFD-induced adipose tissu

281 In the nonwounded tibiae, clodronate treatment significantly increased CD68+ cells

282 maxillary interseptal bone was unaffected by clodronate treatment.

283 Previous findings of adjuvant clodronate trials in different populations with operable

284 Using phosphate, heparin, clodronate, trypan, and suramin, we demonstrate the util

285 Liposome-encapsulated clodronate was also metabolized to AppCCl2p by rat perit

286 increase in extraction socket bone fill with clodronate was less than the large increase in trabecula

287 Liposome-encapsulated clodronate was used to assess macrophage impact on EdCs.

288 By depleting macrophages using liposomal clodronate, we found that alveolarization defects were s

289 LDD and clodronate were given as a single agent or as combinatio

290 iposomes containing the macrophagicidal drug clodronate were used to deplete conjunctival macrophages

291 t-generation bisphosphonates (etidronate and clodronate) were not suitable for long-term treatment an

292 Therefore, we hypothesized that liposomal clodronate would be a useful agent for treating AIHA.